Market news Latest

Creative Diagnostics Launches SARS-CoV-2 Antigens & Antibodies for Research Use

 Breaking News
  • No posts were found

Creative Diagnostics Launches SARS-CoV-2 Antigens & Antibodies for Research Use

March 31
07:24 2020
Creative Diagnostics launches SARS-CoV-2 antigens and antibodies for global researchers.

As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics now launches SARS-CoV-2 antigens and antibodies for global researchers working on the novel coronavirus. These antigens can be used for scientific research, detection of novel coronavirus and preparation of neutralizing antibodies. All of the antigens and antibodies are produced using a standardized production process to ensure the highest quality and are performance guaranteed for the applications.

SARS-CoV-2 (2019-nCoV) is a new type of bat coronavirus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. Early on, many patients in the outbreak in Wuhan, China reportedly had some link to a large seafood and animal market, suggesting animal-to-person spread. However, a growing number of patients reportedly have no exposure to animal markets, indicating person-to-person spread is occurring. At this time, it’s unclear how easily or sustainably this virus is spreading between people.

Creative Diagnostics now provides recombinant SARS-CoV-2 (2019-nCoV) spike, nucleocapsid antigens and antibodies for all scientists. Products such as the Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain [Fc] for ELISA, LFIA, WB, the Recombinant SARS-CoV-2 Nucleocapsid Protein [His] for SDS-PAGE, the Rabbit anti-SARS-CoV-2 NP monoclonal antibody, clone 120 for ELISA, WB, and the Rabbit Anti-SARS-CoV-2 NP Polyclonal antibody for ELISA are all accessible at Creative Diagnostics.

“In response to the pandemic, Creative Diagnostics is dedicated to fighting this disease by continuing to make every effort to work with research institutes and clients around the world to expand the availability of diagnostic tests and stop the spread of the coronavirus. We’ll make sure that all of our SARS-CoV-2-related antigens and antibodies are accessible to our global research clients to fully support the SARS-CoV-2 research and associated diagnostics development,” said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.

“With our expanding line of SARS-CoV-2 antigens and antibodies, we’ll keep to be committed to providing the highest quality reagents to the global scientific community to combat this pandemic. Collaborating with scientists enables us to rapidly provide them with innovative tools and technologies that will help accelerate their work, and we’re looking forward to offering more tools to help fight against the disease,” said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.

If you want to know more information about SARS-CoV-2 antigens and antibodies or other coronavirus research materials, please contact Creative Diagnostics at 1-631-619-7922 or email to [email protected].

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers’ assay development and manufacturing needs.

Media Contact
Company Name: Creative Diagnostics
Contact Person: Thomas Schmitt
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.creative-diagnostics.com